biotech / news / / The Manila Times
Jyong Biotech Ltd. (Nasdaq: MENS) announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 (PCP) conducted in Taiwan.
Jyong Biotech's MCS-8 showed statistically significant cholesterol reduction in a Phase II clinical trial.
KEY POINTS
- No increase in serum LDH was observed in the MCS-8 group, suggesting lower risk of cellular damage.
- Jyong Biotech is considering expanding MCS-8's indications to lipid management and cardiovascular diseases.
- MCS-8's technology enhances bioavailability, potentially enabling multiple dosage forms and indications.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →